Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy

Affiliations

¹ Division of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, IL. Electronic address: michael_jelinek@rush.edu.
² Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
³ University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL.
⁴ Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; AstraZeneca, Cambridge, UK.

Case Reports

Michael J Jelinek et al. Clin Lung Cancer. 2019 Nov.

. 2019 Nov;20(6):e597-e600.

doi: 10.1016/j.cllc.2019.08.002. Epub 2019 Aug 26.

¹ Division of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, IL. Electronic address: michael_jelinek@rush.edu.
² Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
³ University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL.
⁴ Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; AstraZeneca, Cambridge, UK.

No abstract available

Keywords: Circulating tumor DNA; Clonal evolution; EGFR mutation; Liquid biopsy; Resistance mutations.

Publication types